The treatment of otorrhea has been described for more than 3,500 years, but a scientific basis for therapy was laeking untillate in the 20th century. Among the remedies that were used over the centuries were mixtures of red lead, tree resin, and olive oil; frankincense, goose grease, cream from cow's milk, and crushed soda; and vermilion, cumin, ass ear, hatet oil, and olive oil.' In the 1800s, purveyors pitched "rattlesnake oil," which was actually a mixture ofturpentine, camphor, menthol, and sassafras. ' During the first half of the 20th century, various nonspecific methods-including the use of astringents and antiseptics-were the primary forms of treatment for otorrhea secondary to either acute otitis media, acute otitis externa, or chronic suppurative otitis media (CSOM). Although these treatments were potentially ototoxic, no other ototopical preparations were available, and phy sicians had no choice but to aecept the risk .
The development of antibiotics in the middle of the 20th century marked the beginning of a philosophical change in our approach to the treatment of otorrhea. Although practitioners continued to use a variety of preparations, the availability and effectiveness of antimicrobial therapy heralded a newage in the management of draining ears.'
Choosing an antimicrobial
When choosing a particular medication to treat any disease process, physicians today have the advantage of being able to base our choice on sound data regarding the particular characteristics of available drugs. When treating a patient with an infectious disease, rational decision making involves consideration of a drug 's safety; efficacy, spectrum of coverage, and potential for bacterial resistance; cost; and ease of administration and patient compliance.
In the management of otorrhea, antimicrobials can be administered either orally, parenterally, or topically. Depending on the particular disease process, one route might be favored over the others . In most patients with otorrhea, topieal therapy is preferred because it is associated with all the advantages enumerated above, In refractory cases, however, systemic antimicrobial therapy is sometimes necessary and appropriate. In rare instances, tympanoplasty and mastoidectomy are required.
Aminoglycosides. Until recently , the aminoglycoside class of antibiotics-which includes gentamicin, tobramycin, and neomycin-was the primary choice for treating otorrhea. The aminoglycosides are available as both ophthalmic and otic drops. Aminoglycosides are also combined with one of the peptide class of antibiotics (e.g., polymyxin B or polymyxin E) and/or with a steroid (e.g., hydrocortisone or dexamethasone).
Quinolones. In the 1990s, topieal fluoroquinolones began to be used in the treatment of otorrhea. Since then, they have become the treatment of choice, for reasons specified later in this article.
Steroids. Like aminoglycosides, quinolones are also combined with steroids. Before deciding to use any topieal antibiotic/steroid preparation, we must consider the potential problems of steroid use and overuse, including immunologic suppression and hypersensitivity. Inclusion of a steroid with a topieal medication is appropriate when the clinician believes that the benefits outweigh the potential risks , which they doin most cases.
In fact , in a phase III study, Roland et al compared a topieal quinolone/steroid combination (ciprofloxacin/ dexamethasone) with a quinolone alone (ofloxacin) in 599 patients with acute otitis media with otorrhea through tympanostomy tubes (AOMT).2 Patients in the ciprofloxacin/dexamethasone group received 4 drops twice a day for 7 days, and those in the ofloxacin group received 5 drops twice a day for 10 day s (both regimens represent the respective approved dosages for the AOMT indication).
The median time to cess ation of otorrhea was 4 days in the ciprofloxacin/dexamethasone group and 6 days in the ofloxacin group (table) . Clinical cure rates on day 18 (test-of-cure visit) were 90 and 79%, respectively, and the corresponding microbiologic cure rates were 91 and 82%. Failure rates were 5 and 15%, respectively. All of these differences were clinically and statistically significant.
Safety
No commercially available oral agents have an acceptable safety profile forthe treatmentofPseudomonas aeruginosa in children. Topieal agent s are an effective empiric treatment that obviates the need for baseline cultures. In general, the use of a single antimicrobial agent is preferable to the use of multiple antibiotics, because the latter 
Efficacy, coverage, and resistance
The qu in olones' broad spectrum of coverage is in contrast to the limited spec trum that character izes oral prepara-increases the p ot~nt i al for adverse effects.
Ototoxicity-Although it is uncommon, ototoxicity is a known risk of using aminoglycosi des . During the time when no other cho ices were available, thi s risk was consi dere d accepta ble, and it genera Ily did not merit discu ssion with a patient prior to the initiation of therap y. How ev er , sinc e the introduction oft he topie al quinol ones, we now have an alternative that min imizes the risk of hearin g loss and ves tibulotoxicity. As a res ult, one must questi on the wisdo m of using any topieal antimicrobial age nt ot her than a quino lone .
AItho ug h some of the ototoxic risk of the aminoglycosid es is obviated in an intact tympanic membrane, clinici an s mu st stiIl remai n aware of the possib ility that a patient with significant edema of the ear cana l migh t have an unsu sp ected mem brane perforation . Therefore, even in a patient w ith kno wn acute otitis externa, complications ass ociated w ith the use of topieal antimicrobials other than qu inolones are poten tiaIly seve re.
Hyp ersellsitivity. Anot her drawback to the use of aminog lycoside-contain ing drops is their potentia l for hypersens it ivit y. Unfortunate ly, the clinician might not diagn ose hypersensitivity beca use the patient's major sign s and syrnptoms can include red ness, pain , itching, and oth er signs of inflamm ation. The cli nic ian might mi sinte rpret these findin gs as a failure to heal rather than a hypersensitivity reacti on.
Similarly , infl ammation can be caused by agent s such as propyl ene glycol, a solve nt that is ofte n used in top ieal neomyc in/pol yrnyxin B/h ydrocortisone for mulations. Propylene g lyc ol has been shown to cause inflammation in the midd le ear, probably seco ndary to local mucosal irritation.
c ost
Although the initial cost of treatment with an aminoglycos ide or a sulfonamide migh t be tower, the cIinician must kee p in mind that their limited antimicrobial spectrum might requi re the subsequent use of additional parent eral antibiotics or the prolonged use of topi eal therapy, which then increases the overall cost of treatment. Moreove r, the higher incidenee of compl ications and side effects associated with topieal anti biotics other than quin olones might also result in higher costs. Finally , we physician s tend not to think in global terrns, but the rapid resolution of otorr hea wiIl result in less antibiotic resistance and, ultimatel y, less cost to the health eare system. tion s that are frequent ly used in the pediatric population. Likewise, the antibacterial spec trum of ototopica l aminoglycosi des is also limited. Th e quin olones represent an impro vement over other topieal antim icrobials becau se they cover all of the organisms that are co mmo nly encountere d in acute otiti s media, acute otitis externa, and CSO M.
Because the topieal quinolones kill bacteria in a concentration-dependent man ner , local administration ofhigh conce ntrat ions is effective in cau sing a rapid decrease in the density of bacteria. For this reason , bacteri al resistance is quite rare.l? Although a rece nt article" described the em ergence of cip rofloxacin-resistant P aerugin osa in pedi atric otitis media, one must interpret this informati on with cauti on , because the minimum inhibitory concentration for pathogen eradication with qui nolones is reported by the laboratory for sys temic drug administrat ion , not topical.
Summary
A radica l change has occurred in the managem ent of otorrhe a over the past decade. Multiple studies have supported the efficacy of topieal quinolones in the management of acute otit is medi a, acute otit is externa, and CSO M. For the first time, oto laryngologists have a scientific founda tion on which to base our treatm ent pro toco ls for these condi tions. We no longer must rely solely on our clin ical experience and prejudices.
Administration and comp lianee
Depending on the ind ividu al patient, compliance issues are some times an imp ortant factor in the choice of an antimicrobial agent. If one accepts that topieal therapy is preferred to parenteral therapy for otorrhea, qu inolone drops are preferred to other top ieal antibiotics because their do sing schedule ca Ils for less frequent administration . In addition, patient acceptance oftop ical quinolones is goo d because these drugs are genera Ily less acidic than the 01der agent s.r " The quinolone drop s have a superior safety profile and a broad antimicrobial spectrum, their overall cost is lower than the altern atives, and their convenient dosing schedule is tolerated weil by most patients.
When one takes all these factors into con sideration, it becomes clear that topie al quinolone therap y, with or without a steroid additive, is the treatment of cho ice for otorrhea in patients with a tympanic membrane perforation or ventilating tube.
The development of ototopical medications has followed along the lines of Darwinian evolution, and the quinolone drop s have clearly demon strated the concept of "survival of the fittest."
